In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin.
A comparative quantum chemical approach helps to clarify how the selectivity of anticancer metallopharmaceuticals towards potential biological targets can be controlled by metal and ligands.